IL33 and pulmonary fibrosis: Additionally, IL-33 has been implicated in the bleomycin (BLM) mouse model of pulmonary fibrosis with germline ST2 deletion, IL-33 neutralising antibodies and sST2 all leading to reduced lung fibrosis in vivo [16–19].